<?xml version='1.0' encoding='utf-8'?>
<document id="26053556"><sentence text="Decreased elimination clearance of midazolam by doxorubicin through reductions in the metabolic activity of hepatic CYP3A in rats."><entity charOffset="35-44" id="DDI-PubMed.26053556.s1.e0" text="midazolam" /><entity charOffset="48-59" id="DDI-PubMed.26053556.s1.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.26053556.s1.e0" e2="DDI-PubMed.26053556.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26053556.s1.e0" e2="DDI-PubMed.26053556.s1.e1" /></sentence><sentence text="1" /><sentence text=" We examined the effects of doxorubicin (DOX) on the expression level and metabolic activity of CYP3A in the liver as well as on the pharmacokinetics of midazolam (MDZ), a probe for CYP3A, in rats"><entity charOffset="28-39" id="DDI-PubMed.26053556.s3.e0" text="doxorubicin" /><entity charOffset="41-44" id="DDI-PubMed.26053556.s3.e1" text="DOX" /><entity charOffset="153-162" id="DDI-PubMed.26053556.s3.e2" text="midazolam" /><entity charOffset="164-167" id="DDI-PubMed.26053556.s3.e3" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e0" e2="DDI-PubMed.26053556.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e0" e2="DDI-PubMed.26053556.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e0" e2="DDI-PubMed.26053556.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e0" e2="DDI-PubMed.26053556.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e1" e2="DDI-PubMed.26053556.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e1" e2="DDI-PubMed.26053556.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e1" e2="DDI-PubMed.26053556.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e2" e2="DDI-PubMed.26053556.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26053556.s3.e2" e2="DDI-PubMed.26053556.s3.e3" /></sentence><sentence text=" Changes in the hepatic status of DOX-treated rats were confirmed"><entity charOffset="34-36" id="DDI-PubMed.26053556.s4.e0" text="DOX" /></sentence><sentence text=" 2" /><sentence text=" Serum levels of the biomarkers of hepatic impairment were elevated by the DOX treatment, which was consistent with the results obtained from a histopathological evaluation of the liver"><entity charOffset="75-77" id="DDI-PubMed.26053556.s6.e0" text="DOX" /></sentence><sentence text=" 3" /><sentence text=" No significant difference was observed in the expression of proteins for hepatic CYP3A1 and CYP3A2 between the DOX and control groups"><entity charOffset="112-114" id="DDI-PubMed.26053556.s8.e0" text="DOX" /></sentence><sentence text=" The metabolic production of 1'-hydroxylated and 4'-hydroxylated MDZ by hepatic microsomes was significantly lower in DOX-treated rats than in control rats"><entity charOffset="118-120" id="DDI-PubMed.26053556.s9.e0" text="DOX" /><entity charOffset="65-67" id="DDI-PubMed.26053556.s9.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.26053556.s9.e1" e2="DDI-PubMed.26053556.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26053556.s9.e1" e2="DDI-PubMed.26053556.s9.e0" /></sentence><sentence text=" 4" /><sentence text=" The area under the curve (AUC) and the half-life (t1/2) of intravenously administered MDZ were significantly increased, and the total clearance (CLtot) and the elimination rate constant at the terminal phase (ke) were significantly decreased without significant changes in the volume of distribution at a steady state (Vdss)"><entity charOffset="87-89" id="DDI-PubMed.26053556.s11.e0" text="MDZ" /></sentence><sentence text=" 5" /><sentence text=" These results indicated that a DOX-induced depression in the metabolic activity, but not expression level of CYP3A contributed to a decrease in the elimination clearance of MDZ, and also that reduced CYP3A function may be associated with the hepatotoxicity of DOX"><entity charOffset="32-34" id="DDI-PubMed.26053556.s13.e0" text="DOX" /><entity charOffset="261-263" id="DDI-PubMed.26053556.s13.e1" text="DOX" /><entity charOffset="174-176" id="DDI-PubMed.26053556.s13.e2" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.26053556.s13.e0" e2="DDI-PubMed.26053556.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26053556.s13.e0" e2="DDI-PubMed.26053556.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26053556.s13.e0" e2="DDI-PubMed.26053556.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26053556.s13.e2" e2="DDI-PubMed.26053556.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26053556.s13.e2" e2="DDI-PubMed.26053556.s13.e1" /></sentence><sentence text="" /></document>